Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether tigecycline is safe and which dosage is
most effective in the treatment of patients with acute myeloid leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
Memorial Sloan Kettering Cancer Center University of California, Los Angeles University of Kansas